Interpace Biosciences reports record FY2023 revenue $40.2M (+26% YoY), swings to profit of $1.1M.

INTERPACE BIOSCIENCES, INC.

Q4 revenue $10.3M (+23% YoY); Q4 income from cont. ops $0.8M vs loss of $1.4M in prior year.
FY2023 adjusted EBITDA $4.5M (net of one-time charges) vs -$1.2M in 2022, a 463% reported improvement.
Cash collections for FY2023 $40.4M (+29% YoY); cash balance at Dec 31, 2023 was $3.5M.
Dr. Nicole Massoll appointed Chief Medical Officer effective March 2024.
10-K expected week of March 19, 2024; preliminary results subject to final audit.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTERPACE BIOSCIENCES, INC. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.

Period: the fourth quarter and fiscal year ended December 31, 2023
Result: preliminary results

Exact text from the filing

On March 7, 2024, Interpace Biosciences, Inc. issued a press release announcing its preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

INTERPACE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-009737

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.